25389-98-4

Basic information

• Product Name: Neomycin B sulfate
• CAS NO: 25389-98-4
• Molecular Formula: C₂₃H₄₆N₆O₁₃*3H₂O₄S
• Molecular Weight: 908.879
• Mol File: 25389-98-4.mol

Chemical Properties

• Boiling Point: 927.1°Cat760mmHg
• Flash Point: 514.5°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0mmHg at 25°C
• CAS DataBase Reference: Neomycin B sulfate(CAS DataBase Reference)
• NIST Chemistry Reference: Neomycin B sulfate(25389-98-4)
• EPA Substance Registry System: Neomycin B sulfate(25389-98-4)

Safety Data

• Hazardous Substances Data: 25389-98-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C23H46N6O13.H2O4S/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22;1-5(2,3)4/h5-23,30-36H,1-4,24-29H2;(H2,1,2,3,4)

Downstream Products

• 58096-78-9 Hexa-N-(benzyloxycarbonyl)neomycin B 
• 119-04-0 neomycin B 
• 241820-92-8 hexa-N-Boc neomycin B 
• 182554-06-9 5,6,3',4'-tetra-O-acetyl-1,3,2',6'-tetrazidoneamine 
• 182554-04-7 1,3,2′,6′-tetraazido-6,3′,4′-tri-O-acetylneamine 
• 671809-10-2 1,3,2′,6′-tetraazidoneamine 
• 937021-96-0 1,3,2',6'-tetraazido-5-O-methoxymethyl-6,3',4'-tri-O-acetylneamine 
• 937021-98-2 C₁₆H₂₂O₈N₁₂ 
• 937021-97-1 6-O-acetyl-1,3,2',6'-tetraazido-5-O-methoxymethylneamine 
• 937021-95-9 (2R,3R,4R,5R,6R)-3-azido-6-(azidomethyl)-4,5-bis(benzyloxy)-2-(((1R,2R,3S,4R,6S)-4,6-diazido-2,3-bis(benzyloxy)cyclohexyl)oxy)tetrahydro-2H-pyran 
• 15446-43-2 neamine tetrahydrochloride 
• 468065-21-6 hexaazidoneomycin B 
• 98-01-1 furfural 

Relevant articles and documents

METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS

In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

Skin patch for use in contact immunotherapy

A device, preferably in the form of a skin patch, is disclosed for usage in the delivery of a contactant to human skin for the purpose of treating medical conditions responsive to contact immunotherapy, without the presence of medication to alleviate contact dermatitis induced by the contactant. The skin patch specifically induces a cell-mediated contact dermatitis in the treatment of skin disorders. Its anticipated use pertains to treatment of, for example, human papilloma virus infections, or warts. In a first embodiment, a pressure activated single chambered skin patch is topically applied and used for controlled release of contactant to human skin. In a second embodiment, a pressure activated two-chambered skin patch is topically applied and used for controlled release of a contactant to human skin. Alternatively, a single chambered skin patch is topically applied and hydrated by the contacted skin for release of contactant. In an additional embodiment, the contactant may be applied separately of the skin patch portion, in a manner that maintains the contactant in contact with the patient's skin for the predetermined period of time necessary to cause sufficient contact dermatitis to effect resolution of the medical condition.

Oral delivery systems for microparticles

PCT No. PCT/AU92/00141 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Apr. 2, 1992 PCT Pub. No. WO92/17167 PCT Pub. Date Oct. 15, 1992There are disclosed complexes and compositions for oral delivery of a substance or substances to the circulation or lymphatic drainage system of a host. The complexes of the invention comprise a microparticle coupled to at least one carrier, the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host, and the microparticle entrapping or encapsulating, or being capable of entrapping or encapsulating, the substance(s). Examples of suitable carriers are mucosal binding proteins, bacterial adhesins, viral adhesins, toxin binding subunits, lectins, Vitamin B12 and analogues or derivatives of Vitamin B12 possessing binding activity to Castle's intrinsic factor.

Method for apparatus for a defined serumfree medical solution useful for corneal preservation

A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements which maintains and enhances the preservation of eye tissues, including human corneal tissues at low temperatures (2° C. to 15° C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing components, antibiotic(s), ATP precursors and nutrient cell supplements.